| A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging L Keren, M Bosse, D Marquez, R Angoshtari, S Jain, S Varma, SR Yang, ... Cell 174 (6), 1373-1387. e19, 2018 | 794 | 2018 |
| Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines AA Powell, AAH Talasaz, H Zhang, MA Coram, A Reddy, G Deng, ML Telli, ... PloS one 7 (5), e33788, 2012 | 638 | 2012 |
| Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology MB Daly, T Pal, MP Berry, SS Buys, P Dickson, SM Domchek, ... Journal of the National Comprehensive Cancer Network 19 (1), 77-102, 2021 | 589 | 2021 |
| A population-based study of genes previously implicated in breast cancer C Hu, SN Hart, R Gnanaolivu, H Huang, KY Lee, J Na, C Gao, J Lilyquist, ... New England Journal of Medicine 384 (5), 440-451, 2021 | 562 | 2021 |
| Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment AW Kurian, EE Hare, MA Mills, KE Kingham, L McPherson, ... Journal of clinical oncology 32 (19), 2001, 2014 | 522 | 2014 |
| Differences in breast cancer survival by molecular subtypes in the United States N Howlader, KA Cronin, AW Kurian, R Andridge Cancer Epidemiology, Biomarkers & Prevention 27 (6), 619-626, 2018 | 511 | 2018 |
| NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017 MB Daly, R Pilarski, M Berry, SS Buys, M Farmer, S Friedman, JE Garber, ... Journal of the National Comprehensive Cancer Network 15 (1), 9-20, 2017 | 502 | 2017 |
| NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines MB Daly, R Pilarski, MB Yurgelun, MP Berry, SS Buys, P Dickson, ... Journal of the National Comprehensive Cancer Network 18 (4), 380-391, 2020 | 364 | 2020 |
| Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment A Desmond, AW Kurian, M Gabree, MA Mills, MJ Anderson, Y Kobayashi, ... JAMA oncology 1 (7), 943-951, 2015 | 352 | 2015 |
| Genetic/familial high-risk assessment: breast and ovarian MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ... Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010 | 351 | 2010 |
| Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers AW Kurian, BM Sigal, SK Plevritis Journal of Clinical Oncology 28 (2), 222, 2010 | 322 | 2010 |
| Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging SK Plevritis, AW Kurian, BM Sigal, BL Daniel, DM Ikeda, FE Stockdale, ... Jama 295 (20), 2374-2384, 2006 | 322 | 2006 |
| Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients AW Kurian, KC Ward, N Howlader, D Deapen, AS Hamilton, A Mariotto, ... Journal of Clinical Oncology 37 (15), 1305, 2019 | 314 | 2019 |
| Occurrence of breast cancer subtypes in adolescent and young adult women THM Keegan, MC DeRouen, DJ Press, AW Kurian, CA Clarke Breast Cancer Research 14, 1-9, 2012 | 313 | 2012 |
| Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011 AW Kurian, DY Lichtensztajn, THM Keegan, DO Nelson, CA Clarke, ... Jama 312 (9), 902-914, 2014 | 301 | 2014 |
| Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012 SK Plevritis, D Munoz, AW Kurian, NK Stout, O Alagoz, AM Near, SJ Lee, ... Jama 319 (2), 154-164, 2018 | 296 | 2018 |
| Age-specific incidence of breast cancer subtypes: understanding the black–white crossover CA Clarke, THM Keegan, J Yang, DJ Press, AW Kurian, AH Patel, ... Journal of the National Cancer Institute 104 (14), 1094-1101, 2012 | 269 | 2012 |
| Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation–associated breast cancer with assessment of a tumor … ML Telli, KC Jensen, S Vinayak, AW Kurian, JA Lipson, PJ Flaherty, ... Journal of Clinical Oncology 33 (17), 1895, 2015 | 260 | 2015 |
| Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review JL Caswell-Jin, SK Plevritis, L Tian, CJ Cadham, C Xu, NK Stout, ... JNCI cancer spectrum 2 (4), pky062, 2018 | 257 | 2018 |
| Histologic types of epithelial ovarian cancer: have they different risk factors? AW Kurian, RR Balise, V McGuire, AS Whittemore Gynecologic oncology 96 (2), 520-530, 2005 | 250 | 2005 |
